Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Technology

8x8 expands APAC dominance with acquisition of Singapore’s Maven Lab

8x8 (NASDAQ:EGHT), a global leader in integrated cloud communications, announced on Tuesday, January 6, 2026, that it has acquired Maven Lab, a Singapore-based specialist in mobile marketing and enterprise messaging.

The acquisition is a strategic "step-change" for 8x8, designed to cement its leadership in the high-growth Asia-Pacific (APAC) customer engagement market.

By integrating Maven Lab’s team and its acclaimed Moobidesk platform into the 8x8 Platform for CX, the company is pivoting from traditional messaging toward "orchestrated, omnichannel customer journeys."

Moobidesk offers a unified interface for SMS, WhatsApp, Viber, LINE, and voice, featuring smart AI routing and automated response suggestions that have been shown to increase sales leads by an average of 10% for its enterprise clients.

The move comes as the CPaaS (Communications Platform as a Service) market is projected to grow from $32 billion today to nearly $100 billion by 2030.

With Maven Lab’s deep local carrier relationships and regional expertise, 8x8 is now uniquely positioned to support mission-critical, high-volume communications for the finance, healthcare, and logistics sectors across Southeast Asia.

Leia mais: 8x8 expands APAC dominance with acquisition of Singapore’s Maven Lab

Grafa
Health

Marvell Technology accelerates AI networking with $540M XConn acquisition

Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth ​about $540 million, as the chipmaker doubles down on data center hardware ‌amid a race to expand artificial intelligence infrastructure.

Leia mais: Marvell Technology accelerates AI networking with $540M XConn acquisition
Grafa
Health

Johnson & Johnson’s nipocalimab becomes first FcRn blocker to show success in lupus

Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.

Leia mais: Johnson & Johnson’s nipocalimab becomes first FcRn blocker to show success in lupus
Grafa
Health

China approves AUGTYRO™ (Repotrectinib) for NTRK-positive solid tumors

Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).

This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Leia mais: China approves AUGTYRO™ (Repotrectinib) for NTRK-positive solid tumors
Grafa
Agriculture

Appeals court rules against key USDA GMO labeling provisions in win for Natural Grocers

In a significant victory for food transparency advocates, a federal appeals court ruled on January 6, 2026, in favor of Natural Grocers (NASDAQ:NGVC), the Center for Food Safety, and a coalition of plaintiffs.

Leia mais: Appeals court rules against key USDA GMO labeling provisions in win for Natural Grocers
Grafa
Health

Abpro and Celltrion secure FDA clearance for next-gen HER2 "T-cell engager"

Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).

This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.

Leia mais: Abpro and Celltrion secure FDA clearance for next-gen HER2 "T-cell engager"